https://research.patient.info/research/trials/high-grade-ovarian-cancer-nct05456685
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treat
This research study is investigating a new treatment called mirvetuximab soravtansine when given alongside carboplatin for women with specific types of advanced
mirvetuximab soravtansinesecond linecarboplatintreat
https://news.abbvie.com/2018-10-08-ImmunoGen-to-Present-Initial-Data-from-FORWARD-II-Expansion-Cohort-of-Mirvetuximab-Soravtansine-in-Combination-with-KEYTRUDA-at-ESMO
ImmunoGen to Present Initial Data from FORWARD II Expansion Cohort of Mirvetuximab Soravtansine in...
mirvetuximab soravtansineimmunogenpresentinitialdata
https://www.clinicaltrialsarena.com/news/mirvetuximab-soravtansine-ovarian-cancer-data/
ImmunoGen mirvetuximab soravtansine fails Phase III ovarian cancer trial
Aug 9, 2019 - ImmunoGen has reported negative top-line results from the Phase III FORWARD I ovarian cancer trial of mirvetuximab soravtansine.
mirvetuximab soravtansinephase iiiovarian cancerimmunogenfails